Compare
Standard Biotools Inc. vs Siga Technologies Inc vs Zymeworks Inc. vs Zevra Therapeutics, Inc.
| Latest fiscal year | Standard Biotools Inc. LAB | Siga Technologies Inc SIGA | Zymeworks Inc. ZYME | Zevra Therapeutics, Inc. ZVRA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $85.33M | $94.57M | $105.97M | $106.47M |
| Revenue growth (YoY) | -6.2% | -31.8% | +38.9% | +350.9% |
| Gross margin | 49.9% | 68.6% (computed) | n/a | n/a |
| Operating margin | -129.2% | 25.1% | -87.3% | -59.1% |
| Net margin | -87.8% | 24.6% | -76.6% | 78.2% |
| Net income | -$74.90M | $23.28M | -$81.13M | $83.23M |
| EPS (Diluted) | -$0.20 | $0.32 | -$1.08 | $1.35 |
| Operating cash flow | -$74.34M | $43.47M | -$33.01M | -$1.60M |
| Free cash flow | -$82.65M | n/a | -$34.53M | -$2.43M |
| Cash & equivalents | $120.86M | $154.97M | $41.16M | $62.41M |
| Total assets | $567.75M | $219.47M | $346.53M | $284.73M |
| Total liabilities | $143.46M | $20.65M | $78.03M | $130.07M |
| Shareholders' equity | $424.29M | $198.82M | $268.50M | $154.66M |
| Return on year-end equity | -17.7% | 11.7% | -30.2% | 53.8% |
| Shares outstanding | 386.38M | 71.61M | 74.64M | 56.85M |
Revenue, most recent five fiscal years
| Fiscal year | Standard Biotools Inc. | Siga Technologies Inc | Zymeworks Inc. | Zevra Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $85.33M Ended 2025-12-31 | $94.57M Ended 2025-12-31 | $105.97M Ended 2025-12-31 | $106.47M Ended 2025-12-31 |
| 1 year earlier | $91.01M Ended 2024-12-31 | $138.72M Ended 2024-12-31 | $76.30M Ended 2024-12-31 | $23.61M Ended 2024-12-31 |
| 2 years earlier | $106.34M Ended 2023-12-31 | $139.92M Ended 2023-12-31 | $76.01M Ended 2023-12-31 | $27.46M Ended 2023-12-31 |
| 3 years earlier | $97.95M Ended 2022-12-31 | $110.78M Ended 2022-12-31 | $412.48M Ended 2022-12-31 | $10.16M Ended 2022-12-31 |
| 4 years earlier | $130.58M Ended 2021-12-31 | $133.67M Ended 2021-12-31 | $26.68M Ended 2021-12-31 | $28.65M Ended 2021-12-31 |